Pegozafermin. It has two Phase 3 trials: one for MASH and the other for SHTG. See why I continue to rate ETNB stock a buy.

Inc. (NASDAQ:ETNB), with a market capitalization of $1.14 billion, is a clinical-stage biopharmaceutical company focusing on the development of innovative therapies for the treatment of liver and ...

In this article, I noted the prospects that this company is achieving regarding the development of its pipeline drug known as pegozafermin for the treatment of patients with metabolic-associated ...

Leerink Partners analyst Thomas Smith has maintained their bullish stance on ETNB stock, giving a Buy rating on January 2.Stay Ahead of the ...

SAN FRANCISCO - 89bio, Inc. (NASDAQ:ETNB), a biopharmaceutical company specializing in liver and cardiometabolic diseases with a current market capitalization of $1.05 billion, has initiated a public ...

SAN FRANCISCO, Jan. 27, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on ...

(NASDAQ:ETNB), a clinical-stage biopharmaceutical company valued at $937 million, is navigating the complex landscape of metabolic and liver diseases with its lead candidate, pegozafermin.

周二，H.C. Wainwright重申了对89bio Inc. (NASDAQ: ETNB )股票的买入评级和29.00美元的目标价。根据 InvestingPro 数据，该股目前交易价格为6.31美元，接近其52周低点5.99美元，分析师目标价范围从12美元到49美元不等。尽管分析师普遍持强烈共识，暗示存在显著上涨潜力，但投资者应注意该股近期表现疲软，过去一年下跌超过42%。

The company's lead drug candidate, pegozafermin, is currently being evaluated for the treatment of Metabolic Associated Steatohepatitis (MASH), a condition that has garnered significant attention in ...

“We remain confident in pegozafermin’s potential as a potent anti-fibrotic agent with broad cardio-metabolic benefits. With a strengthened leadership team, commercial-scale manufacturing ...

89bio Inc . (NASDAQ:ETNB), a clinical-stage biopharmaceutical company valued at $937 million, is navigating the complex landscape of metabolic and liver diseases with its lead candidate, pegozafermin.